For additional information please contact:
Jan Stålemark, CEO
AroCell AB (publ)
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technologies are based on patented methods to measure TK1 protein levels, which provide valuable information about the speed of cell turnover. A tumor has high cell turnover and as a result TK1 can be detected in the blood with a standard laboratory test, called TK 210 ELISA. The test provides valuable clinical information for prognosis and optimization of treatment strategy. The test may also be used for monitoring disease relapse. For more information, please see www.arocell.com. AroCell is listed at AktieTorget and has about 1 650 shareholders.